logo
Share SHARE
FONT-SIZE Plus   Neg

Novo Nordisk Says FDA Approves To Update Victoza Product Label

Novo Nordisk A/S (NVO) said Friday that the US Food and Drug Administration has approved to update the product label for Victoza to include data showing superior blood sugar control and weight reduction when compared to Januvia. The update also includes data showing the safety and efficacy of adding basal insulin to Victoza and metformin for the treatment of adults with type 2 diabetes.

The label update is based on data from two large, randomized, open-label studies in adults with type 2 diabetes.

"The data from these studies further demonstrate the strong clinical profile and the value of Victoza in the treatment of type 2 diabetes," said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
H&R Block reported a smaller loss for the first quarter, driven by a four percent increase in revenues, partly offset by foreign currency fluctuations. The company announced a $3.5 billion stock buyback, and its shares gained 7% in after-hours trade... About nine-tenths of the world's sea birds are likely to have consumed pieces of plastic which continue to remain in their guts, a study shows. Automakers reported some mixed U.S. sales for August, marked by fewer working days and a delayed Labor Day, even as the month was largely bullish, spurred by lower interest rates, cheaper gas, and some strong employment data that buoyed consumer confidence.
comments powered by Disqus
RELATED NEWS
Trade NVO now with 
Follow RTT